F31 MH119699/MH/NIMH NIH HHS/United States[Grants and Funding] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
2021	1
2022	3
2025	0

Page 1

Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model.

Vermudez SAD, Gogliotti RG, Arthur B, Buch A, Morales C, Moxley Y, Rajpal H, Conn PJ, Niswender CM. Vermudez SAD, et al. Genes Brain Behav. 2022 Jan;21(1):e12752. doi: 10.1111/gbb.12752. Epub 2021 May 28. Genes Brain Behav. 2022. PMID: 34002468 Free PMC article.

Clinical and Preclinical Evidence for M₁ Muscarinic Acetylcholine Receptor Potentiation as a Therapeutic Approach for Rett Syndrome.

Smith M, Arthur B, Cikowski J, Holt C, Gonzalez S, Fisher NM, Vermudez SAD, Lindsley CW, Niswender CM, Gogliotti RG. Smith M, et al. Neurotherapeutics. 2022 Jul;19(4):1340-1352. doi: 10.1007/s13311-022-01254-3. Epub 2022 Jun 7. Neurotherapeutics. 2022. PMID: 35670902 Free PMC article.

Exploration of group II metabotropic glutamate receptor modulation in mouse models of Rett syndrome and MECP2 Duplication syndrome.

Vermudez SAD, Buch A, Weiss K, Gogliotti RG, Niswender CM. Vermudez SAD, et al. Neuropharmacology. 2022 May 15;209:109022. doi: 10.1016/j.neuropharm.2022.109022. Epub 2022 Mar 3. Neuropharmacology. 2022. PMID: 35248529 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year